Wilmington's NiKang Therapeutics closed a $200M Series C
Biotech is to Delaware's future as chemical engineering was to its past. When we talk about tech startups in the First State, we're likely talking about a medical device or therape…
Biotech is to Delaware's future as chemical engineering was to its past. When we talk about tech startups in the First State, we're likely talking about a medical device or therape…